Cooperative Agreement 5802060178

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Assayquant Technologies, Inc. provides $1,093,104 to develop and commercialize a suite of biosensor peptides for the quantitative, high-throughput measurement of oncogenic protein kinases in cell and tissue samples. The key products to be developed and validated under this 2-year award include: Lysate-compatible sensor peptides for measuring activity of mitogen-activated protein kinases (MAPKs)...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $440,287 to GE Medical Systems Information Technologies, Inc. to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This approach aims to democratize biobanking for low-resource institutes by enabling molecular analysis from smaller tumor samples, including those less than 10,000...

This National Science Foundation (NSF) Project Grant award for $380,074, awarded on September 1, 2024, aims to develop a platform for instrument-free, easy-to-interpret quantitative analysis of molecular biomarkers. The project will produce a general methodology adaptable to a range of molecular targets, including potential new agents. The key products to be delivered include: A "yes/no" output for quantitative measurement, enabled through stoichiometry and negative cooperativity-based...

This $440,171 Cooperative Agreement was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Fred Hutchinson Cancer Center in Seattle, Washington to systematically investigate and mitigate the impact of pre-analytical variables on the accuracy and reliability of mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid (CSF) from pediatric brain tumor patients participating in clinical trials. The key objectives are to: (1)...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $419,133.00 to the Massachusetts Institute of Technology (MIT) to develop the AscitesPredict technology. AscitesPredict is a single-cell biosensor platform that uses label-free microscopy and machine learning to evaluate cell identities and therapeutic sensitivities from patient ascites samples. This 3-year project aims to harden the technology for wider research...

The National Cancer Institute (NCI) awarded a $386,700 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the Regents of the University of Minnesota. The grant, titled "Preclinical Development and Validation of Targeted Mass Spectrometry Assays for Serous Ovarian Cancer Diagnosis", will fund research to develop and validate novel multiplexed protein biomarker assays that can differentiate serous ovarian cancer patients from healthy individuals. The...

This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), provides $206,968 to the University of Arizona to develop and validate a gene expression assay called FL24CX. The goal is to use this assay to predict early clinical failure in patients with follicular lymphoma who are treated with immunochemotherapy. The project has two phases: (1) analytical validation of the FL24CX...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

This Project Grant award from the National Institute of Justice under the Forensics Training and Technical Assistance Program (CFDA 16.044) will support a research study by North Carolina State University to assess the performance of droplet digital PCR (ddPCR) for DNA quantification in forensic science applications. The $422,235 award will fund side-by-side experiments comparing ddPCR and traditional quantitative PCR (qPCR) methods to evaluate sensitivity, accuracy, and inhibitor tolerance...